# US 2023/0272389 A1 · CIRCULAR miRNA SPONGES

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272389 A1
- Document ID: US20230272389A1
- Status: Published application
- Kind: A1
- Application number: 18/014,315
- Filed: 2021-07-02
- Published: 2023-08-31
- Earliest claimed: 2020-07-03
- Assignees: National University of Singapore
- Applicants: National University of Singapore
- Inventors: Annadoray Lavenniah; Roger Foo; Matthew Ackers-Johnson
- Web page: https://patentgrep.com/patent/US20230272389A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 35/00: Antineoplastic agents
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/51: in polymeric form, e.g. multimers, concatemers
- C12N 2310/532: Closed or circular
- C12N 2310/533: having a mismatch or nick in at least one of the strands
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to miRNA interference technology. More specifically the invention relates to circular miRNA sponges that carry a plurality of binding sites directed to at least two types of miRNA and separated by random, non-identical spacers, allowing for the inhibition of functional classes of m1RNAs. Preferably, the binding sites are bulged binding sites wherein each bulge is created by a one base deletion and two base mismatch at positions 9-11 nt from the 3′ end of each binding site. Preferably, each spacer is 6 to 24 nucleotides in length. Preferably, the binding sites are against miR-132 and miR-212, miR-17-5p and miR-18a-5p, or miR-20b-5p and miR-106a-5p. Construction vectors and uses of said miRNA sponges for the treatment of diseases, such as cardiomyopathy and cancer, are also disclosed.

## Claims

### Claim 1

An isolated circular RNA polynucleotide microRNA sponge, comprising:
a) a plurality of human or non-human animal microRNA bulged binding sites, wherein each binding site comprises a region which is 100% complementary to a microRNA seed region;
b) a plurality of polynucleotide spacers, wherein each spacer is of 6 to 24 nucleotides and positioned between two binding sites;
wherein said plurality of spacers comprises at least two spacers having a random, non-identical, sequence.

### Claim 2 (depends on 1)

The isolated circular RNA polynucleotide microRNA sponge of claim 1, comprising at least 3 of each of two different microRNA bulged binding sites, and/or
wherein said circular RNA polynucleotide contains a total of 12 microRNA binding sites, and/or
wherein said circular RNA polynucleotide contains spacers of 12 nucleotides in length between the microRNA binding sites, and/or
wherein said different microRNA binding sites are alternated in the circular RNA polynucleotide.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The isolated circular RNA polynucleotide according to claim 1, wherein each bulge is created by a one base deletion and two base mismatches at positions 9-11 nt from the 3′ end of each binding site.

### Claim 7 (depends on 1)

The isolated circular RNA polynucleotide according to claim 1, comprising:
i) human or non-human animal miR-132 microRNA bulged binding sites and human or non-human animal miR-212 microRNA bulged binding sites;
ii) human or non-human animal miR-17-5p microRNA bulged binding sites and human or non-human animal miR-18a-5p microRNA bulged binding sites; or
iii) human or non-human animal miR-20b-5p microRNA bulged binding sites and human or non-human animal miR-106a-5p microRNA bulged binding sites,
wherein each binding site comprises a region which is 100% complementary to the microRNA seed region and is separated by a polynucleotide spacer of eight to twenty nucleotides which comprises a random, non-identical, sequence to reduce repetition of sequences within the sponge and wherein binding sites directed to different microRNA are alternated to reduce repetition of sequences within the sponge.

### Claim 8 (depends on 7)

The isolated circular RNA polynucleotide according to claim 7, comprising twelve bulged binding sites selected from the group comprising, six miR-132 bulged binding sites alternating with six miR-212 bulged binding sites; six miR-17-5p bulged binding sites alternating with six miR-18a-5p bulged binding sites; and six miR-20b-5p bulged binding sites alternating with six miR-106a-5p bulged binding sites; and spacers of twelve nucleotides between each binding site.

### Claim 9 (depends on 7)

The isolated circular RNA polynucleotide according to claim 7, wherein:
i) respective binding sites are complementary to the miR-132 microRNA nucleic acid sequence set forth in 3′-GCUGGUACCGACAUCUGACAAU-5′ (SEQ ID NO: 1) and complementary to the miR-212 microRNA nucleic acid sequence set forth in 3′-ACCGGCACUGACCUCUGACAAU-5′ (SEQ ID NO: 2); or
ii) respective binding sites are complementary to the miR-17-5p microRNA nucleic acid sequence set forth in 3′-CAAAGUGCUUACAGUGCAGGUAG-5′ (SEQ ID NO: 5) and complementary to the miR-18a-5p microRNA nucleic acid sequence set forth in 3′-UAAGGUGCAUCUAGUGCAGAUAG-5′ (SEQ ID NO: 61; or
iii) respective binding sites are complementary to the miR-20b-5p microRNA nucleic acid sequence set forth in 3′-CAAAGUGCUCAUAGUGCAGGUAG-5′ (SEQ ID NO: 9) and complementary to the miR-106a-5p microRNA nucleic acid sequence set forth in 3′-AAAAGUGCUUACAGUGCAGGUAG-5′ (SEQ ID NO: 10).

### Claim 10 (depends on 7)

The isolated circular RNA polynucleotide according to claim 7, wherein:
i) the bulged binding site for miR-132 comprises the nucleic acid sequence set forth in 5′-CGACCAUGGCTCAGACUGUUA-3′ (SEQ ID NO: 3) and the bulged binding site for miR-212 comprises the nucleic acid sequence set forth in 5′-UGGCCGUGACUCCGACUGUUA-3′ (SEQ ID NO: 4);
ii) the bulged binding site for miR-17-5p comprises the nucleic acid sequence set forth in 3′-CTACCTGCACTGATGCACTTTG-5′ (SEQ ID NO: 7) and the bulged binding site for miR-18a-5p comprises the nucleic acid sequence set forth in 3′-CTATCTGCACTACTGCACCTTA-5′ (SEQ ID NO: 8); or
iii) the bulged binding site for miR-20b-5p comprises the nucleic acid sequence set forth in 3′-CTACCTGCACTAACGCACTTTG-5′ (SEQ ID NO: 11) and the bulged binding site for miR-106a-5p comprises the nucleic acid sequence set forth in 3′-CTACCTGCACTGATGCACTTTT-5′ (SEQ ID NO: 12).

### Claim 11 (depends on 10)

The isolated circular RNA polynucleotide according to claim 10, comprising the nucleic acid sequence selected from the nucleic acid sequences set forth in the group comprising:
i) SEQ ID NO: 13, comprising 6 copies of SEQ ID NO: 3 alternating with 6 copies of SEQ ID NO: 4, and 2 copies of spacers SEQ ID NO: 27, 28, 29, 30 and 31 and 1 copy of spacer SEQ ID NO: 32;
ii) SEQ ID NO: 14, comprising 6 copies of SEQ ID NO: 7 alternating with 6 copies of SEQ ID NO: 8, and 2 copies of spacers SEQ ID NO: 27, 28, 29, 30 and 31 and 1 copy of spacer SEQ ID NO: 32; and
iii) SEQ ID NO: 15, comprising 6 copies of SEQ ID NO: 11 alternating with 6 copies of SEQ ID NO: 12, and 2 copies of spacers SEQ ID NO: 27, 28, 29, 30 and 31 and 1 copy of spacer SEQ ID NO: 32.

### Claim 12 (depends on 1)

The isolated circular RNA polynucleotide according to claim 1, for use as a medicament.

### Claim 13 (depends on 12)

The isolated circular RNA polynucleotide according to claim 12, for use in the treatment of:
a) cardiomyopathy, when the circular RNA polynucleotide comprises miR-132 bulged binding sites and miR-212 bulged binding sites; or
b) cancer, when the circular RNA polynucleotide comprises miR-17-5p bulged binding sites and miR-18a-5p bulged binding sites, or comprises miR-20b-5p bulged binding sites and miR-106a-5p bulged binding sites.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising a circular RNA polynucleotide of claim 1; and at least one of a pharmaceutically acceptable diluent, carrier and adjuvant.

### Claim 15 (depends on 1)

An isolated DNA expression construct comprising a nucleic acid sequence encoding the circular RNA polynucleotide according to claim 1, operably linked to a promoter, inverted complementary introns flanking the RNA polynucleotide microRNA sponge sequence, a splice acceptor site (SA) and a splice donor site (SD).

### Claim 16 (depends on 15)

The isolated DNA expression construct of claim 15, comprising a nucleic acid sequence encoding the isolated circular RNA polynucleotide comprising the nucleic acid sequence selected from the nucleic acid sequences set forth in the group comprising:
i) SEQ ID NO: 13, comprising 6 copies of SEQ ID NO: 3 alternating with 6 copies of SEQ ID NO: 4, and 2 copies of spacers SEQ ID NO: 27, 28, 29, 30 and 31 and 1 copy of spacer SEQ ID NO: 32;
ii) SEQ ID NO: 14, comprising 6 copies of SEQ ID NO: 7 alternating with 6 copies of SEQ ID NO: 8, and 2 copies of spacers SEQ ID NO: 27, 28, 29, 30 and 31 and 1 copy of spacer SEQ ID NO: 32; and
iii) SEQ ID NO: 15, comprising 6 copies of SEQ ID NO: 11 alternating with 6 copies of SEQ ID NO: 12, and 2 copies of spacers SEQ ID NO: 27, 28, 29, 30 and 31 and 1 copy of spacer SEQ ID NO: 32.

### Claim 17 (depends on 15)

An expression vector comprising the DNA expression construct of claim 15.

### Claim 18 (depends on 17)

The expression vector of claim 17, wherein the expression vector comprises a constitutive promoter or an inducible promoter, or a cardiac- or cardiomyocyte-specific promoter.

### Claim 19 (depends on 18)

The expression vector of claim 18, wherein the promoter is selected from the group comprising a cardiac troponin T promoter (cTnT), an α-myosin heavy chain (α-MHC) promoter and a myosin light chain (MLC2v) promoter.

### Claim 20 (depends on 17)

The expression vector of claim 17, wherein the expression vector is a virus expression vector selected from the group consisting of Lentivirus, Adenovirus and Adeno-associated virus (AAV).

### Claim 21 (depends on 1)

An isolated circular RNA polynucleotide, pharmaceutical composition, expression construct or expression vector of claim 1 for the treatment, amelioration or prevention of a disease or medical disorder associated with the presence or over-expression of a plurality of microRNA.

### Claim 22 (depends on 21)

The isolated circular RNA polynucleotide of claim 21, wherein the microRNA comprises
miR-132 and miR-212,
miR-17-5p and miR-18a-5p, or
miR-20b-5p and miR-106a-5p.

### Claim 23 (depends on 21)

The isolated circular RNA polynucleotide of claim 21, wherein the disease or medical disorder is:
a) cardiomyopathy, when the circular RNA polynucleotide comprises miR-132 bulged binding sites and miR-212 bulged binding sites; or
b) cancer, when the circular RNA polynucleotide comprises miR-17-5p bulged binding sites and miR-18a-5p bulged binding sites, or comprises miR-20b-5p bulged binding sites and miR-106a-5p bulged binding sites.

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27 (depends on 1)

A method for the treatment, amelioration or prevention of a disease or medical disorder associated with the presence or over-expression of a plurality of microRNA, comprising the step of administering an efficacious amount of a circular RNA polynucleotide of claim 1, a pharmaceutical composition comprising the circular RNA polynucleotide, an expression construct comprising a nucleic acid sequence encoding the circular RNA polynucleotide, or an expression vector comprising the expression construct to a human or non-human animal in need of such treatment.

### Claim 28 (depends on 27)

The method of claim 27, wherein the microRNA comprises
miR-132 and miR-212,
miR-17-5p and miR-18a-5p, or
miR-20b-5p and miR-106a-5p.

### Claim 29 (depends on 27)

The method of claim 27, wherein the disease or medical disorder is:
a) cardiomyopathy, when the circular RNA polynucleotide comprises miR-132 bulged binding sites and miR-212 bulged binding sites; or
b) cancer, when the circular RNA polynucleotide comprises miR-17-5p bulged binding sites and miR-18a-5p bulged binding sites, or comprises miR-20b-5p bulged binding sites and miR-106a-5p bulged binding sites.

### Claim 30

A method of optimizing the structure of a circular RNA polynucleotide microRNA sponge comprising a plurality of bulged binding sites directed to human or non-human animal target miRNA, comprising the steps;
a) test the effect of a plurality of spacers of 6 to 24 nucleotides in length between binding sites, in a circular RNA polynucleotide microRNA sponge comprising a plurality of bulged binding sites directed to one or more human or non-human animal target miRNA, on the binding to their target miRNA, and select the optimum spacer length;
b) test the effect of at least 6 binding sites in total, in a circular RNA polynucleotide microRNA sponge comprising a plurality of bulged binding sites directed to one or more human or non-human animal target miRNA, on the binding to their target miRNA;
c) engineer a circular RNA polynucleotide microRNA sponge comprising the optimum spacer length and number of binding sites from a) and b),
wherein said plurality of spacers comprises at least two spacers having a random, non-identical, sequence.

### Claim 31 (depends on 30)

The method of claim 30, wherein the sponge comprises alternating binding sites.

### Claim 32 (depends on 30)

An isolated circular RNA polynucleotide microRNA sponge produced according to the method of claim 30.
